四天前(2023-10-11) WMS 發表 2024 指引更新
Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update
裡面提到丹木斯的兒童最大劑量是單次 250 mg(筆記在這)
2023-10-07
本來在另一篇寫兒童劑量, 但資料越放越多不方便查詢. 所以另開一篇
小兒 Pediattric 在美國FDA有定義. 指的是16歲以下, 包括嬰兒.幼兒. 幼童, 青少年都算在內.
(資料連結在這. 節錄內容 pediatric age group, from birth to 16 years, including age groups often called neonates, infants, children, and adolescents”). FDA interprets “birth to 16 years” in 21 CFR 201.57(c)(9)(iv)(A) to mean from birth to younger than 17 years old. 2023年4月26日)
下下面這張圖下面這張圖仍是 WMS 2019 update 的內容.
文字部分對於丹木斯的描述. 目前缺乏使用丹木斯治療兒童AMS的研究, 但傳說中(anecdotal 過去的經驗; 奇聞軼事) 是有效. 裡面提到兒童最大劑量是每次 250mg. 與表格內容不同.
小兒 Pediattric 在美國FDA有定義. 指的是16歲以下, 包括嬰兒.幼兒. 幼童, 青少年都算在內.
(資料連結在這. 節錄內容 pediatric age group, from birth to 16 years, including age groups often called neonates, infants, children, and adolescents”). FDA interprets “birth to 16 years” in 21 CFR 201.57(c)(9)(iv)(A) to mean from birth to younger than 17 years old. 2023年4月26日)
在uptodate網站. acetazolamide 小兒藥物資訊, 建議的預防性最大劑量每次 125mg. 治療性的最大劑量每次 250mg
(uptodate引用的資料是 WMS 2010 指引)
(uptodate引用的資料是 WMS 2010 指引)
建議在最高海拔吃 2-3 天之後可停用藥物
下面這張圖是 2019 年WMS的指引更新
Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update
Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update
這張是預防劑量 兒童每公斤 2.5mg. 最大劑量 125mg.

文字部分對於丹木斯的描述. 目前缺乏使用丹木斯治療兒童AMS的研究, 但傳說中(anecdotal 過去的經驗; 奇聞軼事) 是有效. 裡面提到兒童最大劑量是每次 250mg. 與表格內容不同.
最後 2019 WMS 指引更新的結論說, 需要更多研究找出預防及治療兒童高海拔疾病的藥物處方及劑量. 因為提到兒童. 順便放上來.
Conclusions
Conclusions
We have provided evidence-based guidelines for prevention and treatment of acute altitude illnesses, including the
main prophylactic and therapeutic modalities for AMS,
HACE, and HAPE, and recommendations regarding their
role in disease management. Although these guidelines
cover many of the important issues related to prevention
and treatment of altitude illness, several important questions remain to be addressed and should serve as a focus
for future research. Such research includes determining
the optimal rate of ascent to prevent altitude illness, the
role of acetazolamide in HAPE prevention and treatment,
proper dosing regimens for prevention and treatment of altitude illness in the pediatric population, and the role of
staged ascent, preacclimatization, and hypoxic tents in altitude illness prevention.
沒有留言:
張貼留言